AnalystBook Research · Company Intelligence

SOLIGENIX, INC.

SNGXNasdaq

Built from SOLIGENIX, INC.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

The read at a glance

Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.

  • Distress risk · Altman Z-Score -90.05 distress zone — historically elevated failure riskWatch

Where the revenue comes from

Fiscal 2024, as SOLIGENIX, INC. reports it. History and quarterly detail are in the app.

  • Grant$119K

Leadership changes

From SOLIGENIX, INC.'s own filings, the day they're filed.

  • Richard C. Straube · Chief Medical Officer · departureeff. 2025-08-12
  • Timothy R. Cot · member · departureeff. 2023-07-07

Latest filings

  • 10-Q · Quarterly report2026-08-07
  • DEF 14A · Annual proxy (pay & governance)2026-08-03
  • 8-K · Company announcement2026-06-26
  • 8-K · Company announcement2026-06-12
  • 8-K · Company announcement2026-05-28
In the full recordFree for 14 days
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about SOLIGENIX, INC., every answer cited to the official filings🔒
  • The Intelligence Brief — added when SOLIGENIX, INC.'s brief passes our SEC-figure check🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.